Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 21;12:742080. doi: 10.3389/fimmu.2021.742080

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Chen, Jiang, Han, Bai, Ruan, Guo, Zhou, Liang, Yang and Qian

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

DEG expression in different stages of IFX treatment. (A) The non-responders of IFX tended to have a lower pretreatment expression of the downregulated DEGs compared with the responders, and NOX4 displayed the opposite results; (B) the posttreatment expression of the downregulated DEGs exhibited a trend of increases in the responders, and NOX4 exhibited the opposite results; (C) the expression of the downregulated DEGs after treatment in those who responded to IFX was higher than that those who did not respond to IFX, and NOX4 exhibited the opposite results. DEGs, differentially expressed genes; IFX, infliximab; RB, sequencing data of responders before IFX therapy; NRB, sequencing data of non-responders before IFX therapy; RA, sequencing data of responders after IFX therapy; NRA, sequencing data of non-responders after IFX therapy.